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Abstract
Bacterial biofilms show high tolerance towards antibiotics and are a significant problem in clinical settings
where they are a primary cause of chronic infections. Novel therapeutic strategies are needed to improve anti-
biofilm efficacy and support reduction in antibiotic use. Treatment with exogenous nitric oxide (NO) has
been shown to modulate bacterial signaling and metabolic processes that render biofilms more susceptible to
antibiotics. We previously reported on cephalosporin-3'-diazeniumdiolates (C3Ds) as NO-donor prodrugs
designed to selectively deliver NO to bacterial infection sites following reaction with β-lactamases. With
structures based on cephalosporins, C3Ds could, in principal, also be triggered to release NO following β-
lactam cleavage mediated by transpeptidases/penicillin-binding proteins (PBPs), the antibacterial target of
cephalosporin antibiotics. Transpeptidase-reactive C3Ds could potentially show both NO-mediated anti-
biofilm properties and intrinsic (β-lactam-mediated) antibacterial effects. This dual-activity concept was
explored using Streptococcus pneumoniae, a species that lacks β-lactamases but relies on transpeptidases for
cell-wall synthesis. Treatment with PYRRO-C3D (a representative C3D containing the diazeniumdiolate NO
donor PYRRO-NO) was found to significantly reduce viability of planktonic and biofilm pneumococci,
demonstrating that C3Ds can elicit direct, cephalosporin-like antibacterial activity in the absence of β-
lactamases. While NO release from PYRRO-C3D in the presence of pneumococci was confirmed, the anti-
pneumococcal action of the compound was shown to arise exclusively from the β-lactam component and not
through NO-mediated effects. The compound showed similar potency to amoxicillin against S. pneumoniae
biofilms and greater efficacy than azithromycin, highlighting the potential of C3Ds as new agents for treating
pneumococcal infections.
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Abstract 51	
Bacterial biofilms show high tolerance towards antibiotics and are a significant problem in 52	
clinical settings where they are a primary cause of chronic infections. Novel therapeutic 53	
strategies are needed to improve anti-biofilm efficacy and support reduction in antibiotic use. 54	
Treatment with exogenous nitric oxide (NO) has been shown to modulate bacterial signaling 55	
and metabolic processes that render biofilms more susceptible to antibiotics. We previously 56	
reported on cephalosporin-3’-diazeniumdiolates (C3Ds) as NO-donor prodrugs designed to 57	
selectively deliver NO to bacterial infection sites following reaction with β-lactamases. With 58	
structures based on cephalosporins, C3Ds could, in principal, also be triggered to release NO 59	
following β-lactam cleavage mediated by transpeptidases/penicillin-binding proteins (PBPs), 60	
the antibacterial target of cephalosporin antibiotics. Transpeptidase-reactive C3Ds could 61	
potentially show both NO-mediated anti-biofilm properties and intrinsic (β-lactam-mediated) 62	
antibacterial effects. This dual-activity concept was explored using Streptococcus 63	
pneumoniae, a species that lacks β-lactamases but relies on transpeptidases for cell-wall 64	
synthesis. Treatment with PYRRO-C3D (a representative C3D containing the 65	
diazeniumdiolate NO donor PYRRO-NO) was found to significantly reduce viability of 66	
planktonic and biofilm pneumococci, demonstrating that C3Ds can elicit direct, 67	
cephalosporin-like antibacterial activity in the absence of β-lactamases. While NO release 68	
from PYRRO-C3D in the presence of pneumococci was confirmed, the anti-pneumococcal 69	
action of the compound was shown to arise exclusively from the β-lactam component and not 70	
through NO-mediated effects. The compound showed similar potency to amoxicillin against 71	
S. pneumoniae biofilms and greater efficacy than azithromycin, highlighting the potential of 72	
C3Ds as new agents for treating pneumococcal infections.  73	
 74	
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1. Introduction 93	
Bacterial biofilms are widely acknowledged as a significant problem in chronic 94	
clinical infections due to their increased antibiotic tolerance compared to planktonic (free-95	
living) bacteria and their propensity to acquire antimicrobial resistance (AMR). These diverse 96	
bacterial communities have evolved multiple mechanisms that contribute to tolerance. 97	
Adaptive responses, including increased expression of efflux pumps and β-lactamases, along 98	
with restricted diffusion of antibiotics through the biofilm matrix, all confer tolerance. 99	
However, it is the presence of metabolically dormant cells that potentially plays the major 100	
role[1; 2; 3]. Nutrient gradients within biofilms can result in a proportion of the bacterial 101	
population adopting a metabolically dormant state, creating ‘persister’ cells that are highly 102	
tolerant towards antibiotics targeting bacterial growth and reproduction. Biofilm formation 103	
has also been implicated in the development of increased resistance through heightened 104	
mutation frequency and horizontal gene transfer[2]. Novel therapeutic strategies that 105	
overcome antimicrobial tolerance responses, limit development of AMR and reduce reliance 106	
upon conventional antibiotics are needed to create effective new treatments for biofilm-107	
mediated chronic infections. 108	
Nitric oxide (NO) is an ubiquitous signaling molecule across eukaryotic and 109	
prokaryotic systems. The presence of low concentrations of exogenous NO has been shown 110	
to modulate a range of functions in several bacterial species, such as toxin biosynthesis and 111	
protection from oxidative stress[4; 5]. Low NO concentrations also play an important role in 112	
bacterial biofilm biology, where they have been shown to signal a dispersal response in a 113	
broad range of species, including Pseudomonas aeruginosa, Staphylococcus aureus and 114	
Escherichia coli[6]. In Streptococcus pneumoniae, NO treatment of established biofilms was 115	
recently shown to influence metabolism and translational activity, modulating both towards 116	
levels observed in the planktonic phenotype[7]. Use of NO as adjunctive therapy in 117	
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combination with conventional antibiotics has thus emerged as a possible anti-biofilm 118	
strategy because the NO-mediated transition from biofilm to planktonic states renders 119	
bacterial cells more susceptible to antibiotic treatments[7; 8; 9]. 120	
Whilst effective in signaling biofilm dispersal and eliciting other anti-biofilm 121	
responses in vitro, clinical implementation of adjunctive NO therapy with antibiotics in 122	
infectious diseases presents several challenges: (a) NO in gaseous form could only be used 123	
for a limited range of infections (e.g. body surface and bronchopulmonary infections); (b) use 124	
of NO donor compounds that spontaneously release NO in aqueous solution (e.g. sodium 125	
nitroprusside, SNP) for internal infections would present significant toxicity risks due to 126	
systemic exposure of the host to NO[10]; and (c) developing NO-donor/antibiotic 127	
combinations is difficult due to divergent pharmacokinetics and other drug properties of the 128	
two molecules. In addition, the lack of specificity towards bacteria and its short half-life 129	
make NO treatment of biofilm infections challenging[6]. To address these issues, we are 130	
investigating cephalosporin-3´-diazeniumdiolates (C3Ds) as novel, biofilm-activated NO-131	
donor prodrugs. 132	
C3Ds contain a stabilized diazeniumdiolate NO-donor (NONOate) attached at the 3’-133	
position of early generation cephalosporins and were designed to selectively deliver NO to 134	
biofilm infection sites following β-lactam ring cleavage mediated by bacterial β-lactamases. 135	
It was envisaged that the compounds could be used as targeted NO carriers in combination 136	
with conventional antibiotics to treat chronic, β-lactamase expressing, biofilm infections 137	
(Figure 1)[11; 12]. We have previously reported that PYRRO-C3D increases the sensitivity 138	
of non-typeable Haemophilus influenzae biofilms to treatment with azithromycin, a response 139	
that was dependent on NO-release following β-lactamase cleavage[13]. It is conceivable, 140	
however, that liberation of NO from C3Ds might also be triggered by reaction with 141	
transpeptidases/penicillin-binding proteins (PBPs)[11], the molecular target of clinical 142	
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cephalosporin antibiotics, since the mechanism of β-lactam hydrolysis (and ensuing 143	
elimination of the NONOate) by β-lactamases and transpeptidases would be identical (Figure 144	
1). In addition to releasing NO and triggering anti-biofilm responses (including dispersion in 145	
some species), reaction of transpeptidases with the β-lactam of C3Ds should, in principle, 146	
also produce direct antibacterial effects. Dual-activity of this type would support thorough 147	
exploration of C3Ds in a range of infectious disease indications as “all-in-one” anti-biofilm 148	
cephalosporins that don’t require co-administered antibiotics (Figure 1). 149	
 150	
 151	
Figure 1: Mechanism of NO release from cephalosporin-3’-diazeniumdiolates (C3Ds, e.g. 152	
PYRRO-C3D) and proposed effects arising from reaction with PBPs versus β-lactamases. 153	
 154	
S. pneumoniae is a Gram-positive opportunistic pathogen and the causative agent of 155	
various invasive infections, such as meningitis and pneumonia, as well as localized mucosal 156	
infections (e.g. sinusitis and otitis media). Despite introduction of pneumococcal conjugate 157	
vaccines, the clinical incidence of pneumococcal otitis media has stayed largely unchanged 158	
due to serotype replacement, and otitis media remains a primary cause of antibiotic 159	
prescription in children[14; 15; 16; 17; 18]. S. pneumoniae is also a non-β-lactamase-160	
producing organism that uses transpeptidases/PBPs in the construction of its cell wall[19]. 161	
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Treatment with high concentrations of NO has been shown to produce antibacterial effects on 162	
pneumococci when present as in vitro biofilms, on the surfaces of adenoid tissue samples ex 163	
vivo, and in the lungs of mice that develop pneumonia following intranasal infection[7; 20]. 164	
We considered S. pneumoniae an excellent bacterial model to test whether a representative 165	
C3D (i.e. PYRRO-C3D K+ salt, Figure 1) could show direct β-lactam-mediated antibacterial 166	
activity (through reaction with PBPs) and NO-mediated anti-biofilm effects without 167	
confounding effects from β-lactamases. This dual-activity concept was explored by 168	
measuring the direct antibacterial effects of PYRRO-C3D on planktonic and biofilm S. 169	
pneumoniae, and probing whether the observed responses were mediated by PBP inactivation 170	
and/or NO.  171	
 172	
2. Material and Methods 173	
2.1 Bacterial strains and growth conditions.  174	
A S. pneumoniae serotype 14 (ST124) clinical isolate[21] and a Serotype 2 strain (D39) 175	
containing the plasmid pMV158GFP[22] were used in this study. Strains were subcultured 176	
from frozen stocks onto Columbia blood agar (CBA) plates (Oxoid; PB0122), as described 177	
previously[21]. Briefly, cultures were incubated at 37 oC/5% CO2 and colonies re-suspended 178	
in fresh Brain Heart Infusion (BHI) broth (Oxoid; CM1135) for use in experiments. 179	
 180	
2.2 In vitro planktonic experiments.  181	
Flat-bottomed 96-well culture plates (Fisher Scientific) were inoculated with 1.0 x 107 182	
bacteria per well (mid-exponential planktonic cultures) grown in BHI. Stock solutions of 183	
PYRRO-C3D, DEA/NO[7], and cephaloram (all 10 mM in dimethyl sulfoxide, DMSO) were 184	
diluted in BHI and added to wells at final concentrations ranging from 9 nM  ̶  90 µM. 185	
Equivalent BHI volumes with1% DMSO were added in place of treatments for untreated 186	
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controls. Equivalent concentrations of PYRRO-C3D, DEA/NO and cephaloram alone (i.e. in 187	
the absence of bacteria) were used to control for background absorbances. Cultures were 188	
incubated at 37 oC/5% CO2 and the minimum inhibitory concentration (MIC) obtained by 189	
measuring the absorbance (OD595) after 18 hours (EZ Read 400 spectrophotometer, 190	
Biochrom) (n=3).  191	
 192	
2.3 In vitro biofilm experiments.  193	
Mid-exponential planktonic cultures grown in BHI were used to inoculate individual wells of 194	
untreated polystyrene 6-well plates (1 x 108 cells per well) (Corning Incorporated, Costar). 195	
Wells were supplemented with fresh BHI diluted 1:5 with distilled H2O and the cultures 196	
incubated at 37 oC/5% CO2 under static conditions for 48 h. Spent media was replaced with 197	
warm, freshly diluted 1:5 BHI after 24 h. All assays were performed using 2 technical 198	
replicates of 2 biological replicates (n=4). Prior to compound treatment, media was removed 199	
and the biofilms washed twice with 1:5 diluted BHI. PYRRO-C3D, DEA/NO and 200	
cephaloram stock solutions (10 mM in DMSO) were added to wells at final concentrations 201	
ranging from 1 µM  to 100 µM in 1:5 diluted BHI. Equivalent DMSO concentrations (1%) 202	
were maintained for each treatment, including untreated controls. Carboxy-PTIO potassium 203	
salt (cPTIO), clavulanic acid and penicillinase (all Sigma; C221, P3494 and P0389 204	
respectively) were added at final concentrations of 50 µM, 250 µg/mL and 0.01 U/µL, 205	
respectively. For antibiotic co-treatment experiments, amoxicillin and azithromycin (both 206	
Sigma, A8523 and PZ0007 respectively) were added at final concentrations of 300 µg/mL 207	
and 1 mg/mL, respectively. BHI diluted 1:5 with distilled water and containing an equivalent 208	
concentration of DMSO to the treatment solutions (1%) was included as an untreated control. 209	
Biofilms were incubated at 37 oC/5% CO2 for 2 hours, after which the treatments/media were 210	
removed and the remaining biofilms rinsed twice with 1:5 diluted BHI. Biofilms were then 211	
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resuspended in Hank’s balanced salt solution (HBSS), as previously described[23]. In brief, 212	
biofilms were scraped and vortexed and the resuspended biofilms and supernatants diluted in 213	
HBSS, spot-plated onto CBA plates and incubated at 37 oC/5% CO2 for 18 hours before 214	
enumerating colony-forming units (CFUs). Biofilm biomass was measured as previously 215	
described[7].  216	
 217	
2.4 Measurements of nitric oxide release.  218	
NO release from PYRRO-C3D was measured using an ISO-NO probe (World Precision 219	
Instruments) as per manufacturer’s instructions. To quantify the amount of NO released from 220	
PYRRO-C3D in the absence of bacterial cells, HBSS (pH 7.4) was maintained at 37 ± 0.5 oC 221	
with stirring in a septum-sealed acrylic chamber and baseline NO levels were monitored over 222	
5 min. PYRRO-C3D (100 µM) was then added and the NO signal recorded for 5 min before 223	
adding 10 units of Bacillus cereus penicillinase (Sigma; P0389) and monitoring NO levels for 224	
a further 120 min. To measure release of NO from PYRRO-C3D in the presence of 225	
pneumococcal cells, the ISO-NO probe was submerged into the media and positioned directly 226	
above 48 h serotype 14 biofilms (grown as described above). NO concentrations were 227	
monitored over the ensuing 10 minutes to confirm no endogenous NO production, before 228	
adding 100 µM PYRRO-C3D and recording the NO signal for a further 40 minutes. 229	
 230	
2.5 Confocal Laser Scanning Microscopy (CLSM).  231	
Mid-exponential planktonic cultures of serotype 2 strain D39 (containing the plasmid 232	
pMV158GFP) were grown in BHI and used to inoculate 35 mm untreated glass bottom 233	
CELLview cell culture dishes (Greiner Bio One). The dishes were supplemented with fresh 234	
1:5 diluted BHI and biofilms grown under static conditions at 37 oC/5% CO2 for 48 h, 235	
replacing spent media with fresh 1:5 diluted BHI supplemented with 2 % maltose at 24 h (to 236	
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induce gfp expression). Biofilms were then treated with 100 µM PYRRO-C3D or 100 µM 237	
DEA/NO in 1:5 diluted BHI + 2 % maltose, or 1:5 diluted BHI + 2 % maltose (untreated 238	
control), at 37 oC/5% CO2 for 2 h. Treatments/media were removed and the remaining 239	
biofilms rinsed twice with HBSS and stained with propidium iodide according to 240	
manufacturer’s instructions (ThermoFisher Scientific; P3566). Stained biofilms were 241	
examined immediately using a Leica SP8 CLSM with inverted stand under a 63x oil 242	
immersion lens, performing sequential scanning on 0.5 µm sections. The gfp fluorescence 243	
intensity threshold was set to that of planktonic pneumococci to remove background 244	
extracellular DNA staining. Images were analyzed using Leica LCS Software.  245	
 246	
2.6 Statistical analyses.  247	
Statistical analyses of in vitro planktonic and biofilm data were performed using non-248	
parametric Mann-Whitney t-tests. Comparative data reported as p<0.05 were considered 249	
statistically different.  250	
 251	
3. Results 252	
3.1 PYRRO-C3D treatment reduces viability of planktonic and biofilm S. pneumoniae.  253	
NO release from PYRRO-C3D was examined first in the presence of a β-lactamase 254	
(penicillinase) using the NO probe. PYRRO-C3D (100 µM) showed low-level release of NO 255	
over 5 minutes after being added to HBSS (pH 7.4) at 37 ˚C. Subsequent addition of 10 units 256	
of penicillinase caused a rapid spike of NO, reaching a peak concentration of 450 nM within 257	
5 min, which was followed by a steady decline over 2 h, confirming that PYRRO-C3D 258	
efficiently releases NO following β-lactam ring cleavage (Figure 2a). 259	
 260	
	 12	
 261	
Figure 2: Release of NO from PYRRO-C3D. a) NO release from PYRRO-C3D (100 µM) 262	
was monitored following addition to HBSS (pH 7.4) at 37 ˚C. After 5 mins, 10 units of 263	
penicillinase were added, leading to release of NO from PYRRO-C3D. b) 48 h serotype 14 264	
biofilms showed no detectable endogenous NO signal. Addition of 100 µM PYRRO-C3D to 265	
the biofilm triggered release of NO. 266	
 267	
NO measurements on untreated 48 h serotype 14 pneumococcal biofilms showed no 268	
detectable endogenous NO signal (Figure 2b). Treatment with 100 µM PYRRO-C3D 269	
produced a peak of NO release (~100 nM) after 8 minutes, which was followed by a steady 270	
signal corresponding to ~45 nM NO. Detection of the NO signal in the presence of non-β-271	
lactamase producing S. pneumoniae was consistent with PYRRO-C3D undergoing reaction 272	
with transpeptidases/PBPs to liberate PYRRO-NO (and NO). 273	
 Treatment of planktonic cultures with a range of PYRRO-C3D concentrations (9 nM  ̶ 274	
90 µM) identified the MIC as 900 nM, confirming that the compound shows potent 275	
antibacterial activity against planktonic S. pneumoniae cells (Figure 3a). Equivalent 276	
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concentrations of cephaloram, the cephalosporin antibiotic closest in structure to PYRRO-277	
C3D whilst lacking an NO donor, showed identical activity (MIC = 900 nM). Treatment with 278	
equivalent concentrations of the diazeniumdiolate-based spontaneous NO donor DEA/NO, 279	
however, showed no effect on planktonic growth. Collectively, these findings are consistent 280	
with PYRRO-C3D eliciting anti-pneumococcal effects through reaction of its cephalosporin 281	
β-lactam with PBPs and that, although NO is released from the compound during this 282	
process, it does not contribute directly to the antibacterial effect. 283	
 284	
 285	
Figure 3: Effects of DEA/NO, cephaloram and PYRRO-C3D on the viability of in vitro 286	
S. pneumoniae planktonic cells and biofilms. a) Planktonic S. pneumoniae serotype 14 287	
(ST124) cultures were treated with DEA/NO, cephaloram or PYRRO-C3D for 18 hours and 288	
absorbance (OD595) was measured to determine the minimum inhibitory concentration. b) 48 289	
h serotype 14 biofilms were treated with DEA/NO, cephaloram or PYRRO-C3D for 2 hours 290	
before measuring cell viability in the remaining biofilm population. *p≤0.05. 291	
 292	
A range of PYRRO-C3D concentrations (10 nM - 100 µM) were tested next against 293	
mature (48 hour) in vitro S. pneumoniae biofilms. A two hour treatment time was 294	
investigated based on previous studies that demonstrated i) the response of pneumococcal 295	
biofilms to exogenous NO[7], and ii) the antimicrobial effect of PYRRO-C3D on non-296	
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typeable H. influenzae biofilms[13] following 2 hour treatments. The treatment time was also 297	
chosen based on the NO release profile of PYRRO-C3D whereby little measurable NO was 298	
remaining after 2 hours following activation (Figure 2a). Biofilms were assessed for 299	
pneumococcal viability by CFU enumeration showed a concentration-dependent response to 300	
PYRRO-C3D, culminating in a 3-log reduction in biofilm CFUs at 100 µM (p=0.014) (Figure 301	
3b).  As seen in the planktonic phenotype, cephaloram showed identical activity to PYRRO-302	
C3D (3-log reduction in biofilm CFUs at 100 µM, p=0.029) and DEA/NO showed no effect 303	
below 100 µM (p=0.49). A 4-log reduction was also observed in CFUs grown from the 304	
supernatant surrounding PYRRO-C3D (100 µM) treated cells, compared to untreated controls 305	
(p=0.029, data not shown). 306	
CLSM imaging and biomass measurements of 48 hour biofilms formed by a GFP-307	
expressing serotype 2 strain (D39) showed no change in maximum biofilm height (p=0.57) or 308	
total biomass (p=0.989) following treatment with either 100 µM DEA/NO or PYRRO-C3D 309	
(Figure 4a & b), demonstrating that neither compound triggers an NO-mediated dispersal 310	
response in pneumococcus.  While this is in contrast to the robust dispersal responses seen 311	
following C3D treatment of P. aeruginosa biofilms and NO treatment of biofilms from other 312	
bacteria[8; 9], it is consistent with our recent results showing that NO modulates metabolic 313	
activity but not dispersal in S. pneumoniae biofilms[7]. Similar to the CFU data, treatment 314	
with DEA/NO showed no effect on biofilm viability, whereas a significant reduction in 315	
biofilm viability was observed following PYRRO-C3D treatment (Figure 4c, - e). 316	
 317	
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 318	
Figure 4: Effects of PYRRO-C3D on S. pneumoniae serotype 2 (D39) in vitro biofilms. 319	
Established 48 h D39 biofilms expressing GFP were treated with 100 µM PYRRO-C3D or 320	
DEA/NO for 2 hours and imaged using confocal microscopy. Biofilms were counterstained 321	
with propidium iodide to distinguish dead cells from GFP-expressing viable cells (green). 322	
Treatment with DEA/NO and PYRRO-C3D had no effect on either a) maximum biofilm 323	
height, or b) biofilm biomass compared to untreated controls. Treatment with PYRRO-C3D, 324	
and not DEA/NO, reduced the number of viable bacteria present within the biofilm (c-e). 325	
 326	
3.2 Activity of PYRRO-C3D against pneumococcal biofilms is exclusively mediated 327	
through the cephalosporin β-lactam.  328	
Having established that 100 µM PYRRO-C3D was effective in reducing 329	
pneumococcal viability in biofilms (Figure 3), the treatment was repeated in the presence of 330	
the β-lactamase inhibitor clavulanic acid (250 mg.mL-1). No change in the response to 331	
PYRRO-C3D was observed (p=0.929) (Fig. 5a), confirming that β-lactamases were playing 332	
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no part in the compound’s activity. Treatment of biofilms with 100 µM PYRRO-C3D was 333	
next repeated in the presence of the NO-scavenger cPTIO. Addition of 50 µM cPTIO, which 334	
showed no effect on its own, did not change the activity of PYRRO-C3D (p=0.829, Fig. 5b), 335	
confirming that the NO being released from PYRRO-C3D was having no effect. The effect of 336	
PYRRO-C3D on S. pneumoniae viability was then assessed in the presence of 0.01 U/µL 337	
penicillinase, the same β-lactamase shown to cleave the β-lactam of PYRRO-C3D and 338	
liberate NO (Figure 2). Addition of penicillinase significantly reduced the activity of 339	
PYRRO-C3D (p=0.0286, Fig. 5c). Together these data provide compelling evidence that 340	
PYRRO-C3D produces direct activity against biofilm pneumococci via reaction of its 341	
cephalosporin β-lactam with transpeptidases/PBPs only, and that subsequent release of NO 342	
from the compound produces no measurable effect on cell viability. 343	
 344	
 345	
Figure 5: Response of S. pneumoniae serotype 14 (ST124) in vitro biofilms to PYRRO-346	
C3D treatment in the presence of clavulanic acid, cPTIO and penicillinase. 48 h S. 347	
pneumoniae biofilms were treated with 100 µM PYRRO-C3D for 2 h in the presence of a) 348	
250 µg/mL clavulanic acid, b) 50 µM cPTIO and c) 0.01 unit/µL penicillinase. Pneumococcal 349	
viability in biofilms following treatment was assessed by CFU enumeration. *p≤0.05. 350	
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3.3 PYRRO-C3D shows similar activity to amoxicillin and is more active than 352	
azithromycin against pneumococcal biofilms.  353	
The anti-biofilm activity of PYRRO-C3D was next compared to amoxicillin and 354	
azithromycin, two antibiotics commonly prescribed for the treatment of S. pneumoniae 355	
infections. Established pneumococcal serotype 14 and serotype 2 biofilms were treated for 2 356	
hours with 100 µM PYRRO-C3D, supra-MIC concentrations of amoxicillin (300 µg/mL) or 357	
azithromycin (1 mg/mL), and bacterial viability was assessed by CFU enumeration. PYRRO-358	
C3D and amoxicillin both produced 3-log reductions in viability against serotype 14 and 2-359	
log reductions against serotype 2 (Fig. 6a & b). Treatment with azithromycin, a non-β-lactam 360	
(macrolide) antibiotic, showed no significant effects on serotype 14 (p=0.582) or serotype 2 361	
(p=0.829) viability.  362	
 363	
 364	
Figure 6: Comparison of the antibacterial activities of PYRRO-C3D, amoxicillin and 365	
azithromycin against S. pneumoniae serotype 14 (ST124) and serotype 2 (D39) in vitro 366	
biofilms. Established 48 h a) serotype 14 and b) serotype 2 biofilms were treated with 100 367	
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µM PYRRO-C3D, 300 µg/mL amoxicillin or 1 mg/mL azithromycin for 2 hours and assessed 368	
for pneumococcal viability by CFU enumeration. *p≤0.05; ***p≤0.001. 369	
 370	
4. Discussion 371	
Previous studies showed that low levels of NO were released from our prototype C3D 372	
(DEA-CP) in the presence of non-β-lactamase producing E. coli cell extracts[11] and it was 373	
postulated that the NO release resulted from reaction of the compound with PBPs, the 374	
enzymes responsible for cross-linking peptidoglycan chains during bacterial cell wall 375	
synthesis. It is well known that cephalosporins and other β-lactam antibiotics elicit 376	
antibacterial effects by covalently binding to the active sites of PBPs in a process that also 377	
results in β-lactam ring cleavage[24].  This led us to speculate that reactions between PBPs 378	
and C3Ds might elicit a direct, β-lactam-mediated antibacterial effect and in the process 379	
liberate the NONOate (and NO) (Fig. 1). Since anti-biofilm effects of NO are now well 380	
documented, we postulated that NO released from C3Ds following reaction with PBPs might 381	
confer additional anti-biofilm activity.  382	
We tested this dual-activity hypothesis using non-β-lactamase producing S. 383	
pneumoniae strains that express five high molecular weight PBPs (1a, 1b, 2a, 2b and 2x) and 384	
one low molecular weight PBP3[19]. The absence of β-lactamases ensured that NO released 385	
from the compound must arise from an alternative mechanism, most likely PBP-mediated β-386	
lactam cleavage. The representative C3D selected for the study was PYRRO-C3D, a close 387	
structural analogue of DEA-CP that carries PYRRO/NO (t1/2 = 2 secs) as the NONOate 388	
instead of DEA/NO (t1/2 = 2 min)[25]. PYRRO-C3D was chosen for its faster NO release, 389	
which we believe would be important for C3D use in vivo since diffusion of an expelled 390	
NONOate away from infection sites (before releasing the NO cargo) would reduce 391	
effectiveness and raise NO-mediated safety concerns. 392	
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The ability of PYRRO-C3D to release NO following β-lactam cleavage was 393	
confirmed first by treating the compound with penicillinase and directly observing NO. 394	
Release of NO from PYRRO-C3D in the presence of S. pneumoniae cells lacking β-395	
lactamase was demonstrated, consistent with S. pneumoniae PBPs hydrolysing the 396	
compound’s β-lactam and triggering release of NO. PYRRO-C3D was then shown to reduce 397	
viability of both planktonic and biofilm S. pneumoniae, confirming that the compound shows 398	
direct antibacterial activity against this bacterium. The level of activity was consistent with 399	
the known tendency of biofilms to be less susceptible to antimicrobial treatments than their 400	
planktonic counterparts[26; 27; 28], since treatment with 900 nM PYRRO-C3D completely 401	
inhibited planktonic growth, whereas a significant reduction in biofilm viability (3-log) 402	
required more than 100-fold higher concentrations.  403	
β-lactamases were confirmed as playing no role in PYRRO-C3D’s activity since no 404	
difference was seen in the presence of the β-lactamase inhibitor clavulanic acid. Absence of 405	
antibacterial activity when planktonic and biofilm cultures were treated with the spontaneous 406	
NO-donor DEA/NO provided evidence that the effects of PYRRO-C3D against 407	
pneumococcus are exclusively due to its cephalosporin β-lactam core and are not NO 408	
mediated.  We further observed that the cephalosporin equivalent of PYRRO-C3D lacking a 409	
NONOate (i.e. cephaloram) showed identical activity to PYRRO-C3D, and that addition of 410	
the NO-scavenger cPTIO failed to change PYRRO-C3D activity. Moreover, PYRRO-C3D 411	
significantly reduced (4-log) the number of viable planktonic bacteria remaining in the 412	
surrounding media, likely due to the direct antibacterial effect of PYRRO-C3D. Confocal 413	
imaging and measurements of biomass showed that no significant reduction in biofilm 414	
maximum height or biomass occurred following PYRRO-C3D treatment, but there was a 415	
significant reduction in the number of viable bacteria remaining within biofilms, validating 416	
the reduction in CFUs. These findings together were consistent with PYRRO-C3D acting 417	
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directly as a cephalosporin-like β-lactam antibiotic, a notion further supported by its reduced 418	
activity in the presence of penicillinase. 419	
Finally, the antibacterial activity of PYRRO-C3D towards pneumococcal biofilms 420	
was compared with that of antibiotics commonly used to treat pneumococcal infections. We 421	
found that PYRRO-C3D possessed similar antibacterial efficacy to amoxicillin against both 422	
serotype 2 and 14 biofilms, which is perhaps not surprising given that the compounds are 423	
structurally and functionally very similar, with both targeting PBP-mediated cell wall 424	
synthesis. PYRRO-C3D was found to be much more effective than azithromycin, an 425	
antibiotic that targets protein biosynthesis. 426	
The findings presented here are consistent with our recent study, which showed that 427	
high concentrations of NO (1 mM) are needed to elicit bactericidal effects or enhance 428	
antibiotic efficacy against four different serotypes of pneumococcal in vitro biofilms[7]. The 429	
current study demonstrated that PYRRO-C3D at 100 µM liberates maximum NO 430	
concentrations of ~450 nM and 100 nM upon contact with penicillinase and pneumococcal 431	
cells, respectively. It therefore seems likely that PYRRO-C3D does not release sufficient NO 432	
when activated by PBPs to modulate pneumococcal biofilm metabolism towards the 433	
planktonic phenotype in vitro. This may, however, not be the case in the upper respiratory 434	
tract, for example, where the constitutive release of NO by host cells could have an 435	
augmentative effect, as observed in our recent study where an anti-pneumococcal response to 436	
100 µM NO was seen on host adenoid tissue[7]. 437	
 In summary, this study demonstrated that a representative C3D (PYRRO-C3D) 438	
releases NO and shows direct antibacterial effects against planktonic and biofilm forms of 439	
non-β-lactamase producing S. pneumoniae. The activity was confirmed to arise exclusively 440	
from β-lactam mediated reactions with S. pneumoniae PBPs, with no measurable contribution 441	
coming from the released NO. In the treatment of pneumococcal biofilms, PYRRO-C3D was 442	
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found to be equally as effective as amoxicillin and more effective than azithromycin when 443	
used alone. 444	
 445	
5. Conclusions 446	
Introduction of a diazeniumdiolate at the cephalosporin 3’-position was shown for the 447	
first time to be structurally compatible with binding to the molecular target of β-lactam 448	
antibiotics, PBPs. Medicinal chemistry tuning of the cephalosporin aminoacyl side chain and 449	
diazeniumdiolate portions may identify C3Ds with PBP-mediated activity against other 450	
species, and perhaps even broad-spectrum activity. While the study did not demonstrate that 451	
PYRRO-C3D produces combined NO and β-lactam based anti-biofilm effects against S. 452	
pneumoniae, it is possible that such dual-effects might be observed with C3Ds in other 453	
species and with other analogues. Non-β-lactamase producing bacteria that undergo NO-454	
mediated biofilm dispersion would be of particular interest for future study.   455	
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